Drug
Liposomal Irinotecan
Liposomal Irinotecan: highest development phase Phase 2, developed by Servier. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| Liposomal Irinotecan NCT03764553 | Phase 2 | Esophageal Cancer |
Latest
No recent events.
Follow Liposomal Irinotecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.